152 related articles for article (PubMed ID: 23221858)
21. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
22. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Cruz HG; Hay JL; Hoever P; Alessi F; te Beek ET; van Gerven JM; Dingemanse J
Eur Neuropsychopharmacol; 2014 Aug; 24(8):1257-68. PubMed ID: 24880753
[TBL] [Abstract][Full Text] [Related]
24. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
25. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
Nichols AI; Lubaczewski S; Liang Y; Matschke K; Braley G; Ramey T
Int J Clin Pharmacol Ther; 2014 Oct; 52(10):830-41. PubMed ID: 25138680
[TBL] [Abstract][Full Text] [Related]
26. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
[TBL] [Abstract][Full Text] [Related]
27. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
Bergmann TK; Bathum L; Brosen K
Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
[TBL] [Abstract][Full Text] [Related]
28. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
Gallagher JC; Strzinek RA; Cheng RF; Ausmanas MK; Astl D; Seljan P
J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
30. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
Tourian K; Wang Y; Ii Y
Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982
[TBL] [Abstract][Full Text] [Related]
31. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
Khan AY; Preskorn SH; Horst WD
J Pak Med Assoc; 2007 May; 57(5):230-5. PubMed ID: 17571477
[TBL] [Abstract][Full Text] [Related]
32. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
33. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
[TBL] [Abstract][Full Text] [Related]
34. Desvenlafaxine: another "me too" drug?
Sopko MA; Ehret MJ; Grgas M
Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
[TBL] [Abstract][Full Text] [Related]
35. Phenobarbital induces the 2-hydroxylation of desipramine.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
[TBL] [Abstract][Full Text] [Related]
36. Managing rapid metabolizers of antidepressants.
Kraus RP; Diaz P; McEachran A
Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
[TBL] [Abstract][Full Text] [Related]
37. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.
Findling RL; Groark J; Tourian KA; Ramaker SA; Chiles D; Yang L; Nichols AI
J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):909-921. PubMed ID: 27428303
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
40. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
